Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?

J Thorac Oncol. 2023 Dec;18(12):1621-1624. doi: 10.1016/j.jtho.2023.09.1438.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Crizotinib
  • Drug Resistance, Neoplasm
  • Humans
  • Lung Neoplasms*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Receptor Protein-Tyrosine Kinases
  • Tyrosine Kinase Inhibitors*

Substances

  • Crizotinib
  • Protein Kinase Inhibitors
  • Receptor Protein-Tyrosine Kinases
  • Tyrosine Kinase Inhibitors